Tafenoquine
- Generic Name
- Tafenoquine
- Brand Names
- Arakoda, Krintafel
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28F3N3O3
- CAS Number
- 106635-80-7
- Unique Ingredient Identifier
- 262P8GS9L9
- Background
Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoquine was further developed collaboratively between GlaxoSmithKline and Medicines for Malaria Venture. It was FDA approved on July 20, 2018.
- Indication
用于16岁及以上疟疾患者，根治(预防复发)由间日疟原虫(P.vivax)导致的疟疾。
- Associated Conditions
- Malaria caused by plasmodium vivax
- Associated Therapies
- -
Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults
Phase 2
Terminated
- Conditions
- MalariaPlasmodium Vivax
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- U.S. Army Medical Research and Development Command
- Target Recruit Count
- 70
- Registration Number
- NCT01290601
- Locations
- 🇹🇭
Bangkok Hospital for Tropical Diseases/Mahidol University, Bangkok, Thailand
G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 192
- Registration Number
- NCT01205178
- Locations
- 🇹🇭
GSK Investigational Site, Tak, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath